首页 > 最新文献

Wspolczesna Onkologia-Contemporary Oncology最新文献

英文 中文
Colorectal cancer radiotherapy utilization rate in a low-middle income country - a multicenter study in Indonesia. 中低收入国家的结直肠癌放疗使用率——印度尼西亚的一项多中心研究。
IF 2.9 Q2 ONCOLOGY Pub Date : 2025-01-01 Epub Date: 2025-04-09 DOI: 10.5114/wo.2025.149236
Vito Filbert Jayalie, Gregorius Ben Prajogi, Tiara Bunga Mayang Permata, Handoko, Soehartati Gondhowiardjo

Introduction: Despite the rising application of radiotherapy for cancer in Indonesia, no known radiotherapy utilization rate (RUR) figure has been produced for colon and rectal cancer in Indonesia. This study aims to depict the actual and optimal RUR for colon and rectal cancer in Indonesia.

Material and methods: Secondary data was obtained from hospitals providing radiotherapy services in Indonesia, and descriptive analysis was conducted in April-September 2022.

Results: Actual RUR (aRUR) of colon cancer was 5.3%, yet the calculated optimal RUR (oRUR) was 3.3% (3-3.7%) with an unmet need percentage of -60.6% [-76.7-(-43.2)%]. Actual RUR of rectal cancer in Indonesia was 19.5%, while calculated oRUR was 41% (28-66%) with an unmet need percentage of 52.4% (30.4-70.5%). In combination, 26.21% and 14.9% were the final calculation of colorectal cancer oRUR and aRUR, resulting in 45.5% (21.4-65.6%) unmet need. A substantial difference was also observed when sensitivity analysis was incorporated, with the percentage of unmet needs for colon and rectal cancer ranging from -76.7 to 86.5% and 2.2-94.2%, respectively.

Conclusions: There is a gap between aRUR and oRUR of colorectal cancer. Although oRUR of colon cancer seems to have been met, a significant gap persisted between oRUR and aRUR in rectal cancer. However, when sensitivity analysis was incorporated, notable disparity persisted for both colon and rectal cancer. Patient, clinician, and bureaucratic factors should be considered in increasing the RUR of colon and rectal cancer.

导论:尽管印度尼西亚癌症放疗的应用越来越多,但目前尚无已知的印度尼西亚结肠癌和直肠癌放疗利用率(RUR)数据。本研究旨在描述印度尼西亚结直肠癌的实际和最佳RUR。材料和方法:从印度尼西亚提供放疗服务的医院获得二级数据,并于2022年4月至9月进行描述性分析。结果:结肠癌实际RUR (aRUR)为5.3%,计算最佳RUR (oRUR)为3.3%(3-3.7%),未满足率为-60.6%[-76.7-(-43.2)%]。印度尼西亚直肠癌的实际RUR为19.5%,计算oRUR为41%(28-66%),未满足需求比例为52.4%(30.4-70.5%)。结直肠癌oRUR和aRUR的最终计算分别为26.21%和14.9%,有45.5%(21.4-65.6%)未满足需求。当纳入敏感性分析时,也观察到实质性差异,结肠癌和直肠癌未满足需求的百分比分别为- 76.7%至86.5%和2.2-94.2%。结论:结直肠癌的aRUR与oRUR存在差距。虽然结肠癌的oRUR似乎已经达到,但直肠癌的oRUR和aRUR之间仍然存在显著差距。然而,当纳入敏感性分析时,结肠癌和直肠癌的显著差异仍然存在。提高结直肠癌RUR应综合考虑患者、临床医师和官僚因素。
{"title":"Colorectal cancer radiotherapy utilization rate in a low-middle income country - a multicenter study in Indonesia.","authors":"Vito Filbert Jayalie, Gregorius Ben Prajogi, Tiara Bunga Mayang Permata, Handoko, Soehartati Gondhowiardjo","doi":"10.5114/wo.2025.149236","DOIUrl":"https://doi.org/10.5114/wo.2025.149236","url":null,"abstract":"<p><strong>Introduction: </strong>Despite the rising application of radiotherapy for cancer in Indonesia, no known radiotherapy utilization rate (RUR) figure has been produced for colon and rectal cancer in Indonesia. This study aims to depict the actual and optimal RUR for colon and rectal cancer in Indonesia.</p><p><strong>Material and methods: </strong>Secondary data was obtained from hospitals providing radiotherapy services in Indonesia, and descriptive analysis was conducted in April-September 2022.</p><p><strong>Results: </strong>Actual RUR (aRUR) of colon cancer was 5.3%, yet the calculated optimal RUR (oRUR) was 3.3% (3-3.7%) with an unmet need percentage of -60.6% [-76.7-(-43.2)%]. Actual RUR of rectal cancer in Indonesia was 19.5%, while calculated oRUR was 41% (28-66%) with an unmet need percentage of 52.4% (30.4-70.5%). In combination, 26.21% and 14.9% were the final calculation of colorectal cancer oRUR and aRUR, resulting in 45.5% (21.4-65.6%) unmet need. A substantial difference was also observed when sensitivity analysis was incorporated, with the percentage of unmet needs for colon and rectal cancer ranging from -76.7 to 86.5% and 2.2-94.2%, respectively.</p><p><strong>Conclusions: </strong>There is a gap between aRUR and oRUR of colorectal cancer. Although oRUR of colon cancer seems to have been met, a significant gap persisted between oRUR and aRUR in rectal cancer. However, when sensitivity analysis was incorporated, notable disparity persisted for both colon and rectal cancer. Patient, clinician, and bureaucratic factors should be considered in increasing the RUR of colon and rectal cancer.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 1","pages":"113-122"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Circulating tumor DNA - from biology to potential clinical applications in diffuse large B-cell lymphomas. 循环肿瘤DNA -从生物学到弥漫性大b细胞淋巴瘤的潜在临床应用。
IF 2.9 Q2 ONCOLOGY Pub Date : 2025-01-01 Epub Date: 2025-05-09 DOI: 10.5114/wo.2025.150452
Krzysztof Lewandowski, Kinga Gwóźdź-Bąk

During the last 20 years, significant progress has been made in understanding the biology of cancer cells. Assessment of the molecular profile of neoplastic cells collected by tissue biopsy using next-generation sequencing techniques makes it possible to diagnose the specific diffuse large B-cell lymphoma subtype and to personalize the therapy applied through the rational use of molecularly targeted drugs. Similar to the other methods of biopsy material evaluation, this method has some limitations. It may fail in cases when tissue biopsies do not fully capture intratumor genetic heterogeneity. For this reason, research has been undertaken to find new laboratory methods to study the genetic heterogeneity of cancer cells and to characterize all lymphoma cells at once, regardless of the origin of the tumor cells and the stage of its transformation. One promising diagnostic approach is the evaluation of total free circulating DNA, including circulating tumor DNA, using molecular biology techniques.

在过去的20年里,在了解癌细胞的生物学方面取得了重大进展。利用新一代测序技术对组织活检收集的肿瘤细胞的分子谱进行评估,可以诊断特异性弥漫性大b细胞淋巴瘤亚型,并通过合理使用分子靶向药物来个性化治疗。与其他活检材料评估方法类似,该方法有一定的局限性。当组织活检不能完全捕获肿瘤内遗传异质性时,它可能会失败。因此,研究人员一直在寻找新的实验室方法来研究癌细胞的遗传异质性,并同时表征所有淋巴瘤细胞,而不考虑肿瘤细胞的起源和转化阶段。一种有前途的诊断方法是利用分子生物学技术评估总游离循环DNA,包括循环肿瘤DNA。
{"title":"Circulating tumor DNA - from biology to potential clinical applications in diffuse large B-cell lymphomas.","authors":"Krzysztof Lewandowski, Kinga Gwóźdź-Bąk","doi":"10.5114/wo.2025.150452","DOIUrl":"10.5114/wo.2025.150452","url":null,"abstract":"<p><p>During the last 20 years, significant progress has been made in understanding the biology of cancer cells. Assessment of the molecular profile of neoplastic cells collected by tissue biopsy using next-generation sequencing techniques makes it possible to diagnose the specific diffuse large B-cell lymphoma subtype and to personalize the therapy applied through the rational use of molecularly targeted drugs. Similar to the other methods of biopsy material evaluation, this method has some limitations. It may fail in cases when tissue biopsies do not fully capture intratumor genetic heterogeneity. For this reason, research has been undertaken to find new laboratory methods to study the genetic heterogeneity of cancer cells and to characterize all lymphoma cells at once, regardless of the origin of the tumor cells and the stage of its transformation. One promising diagnostic approach is the evaluation of total free circulating DNA, including circulating tumor DNA, using molecular biology techniques.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 2","pages":"150-158"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction for: Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study Group. 更正:加速慢性淋巴细胞白血病-波兰成人白血病研究组的特征和回顾性分析。
IF 1.3 Q2 ONCOLOGY Pub Date : 2025-01-01 Epub Date: 2025-09-17 DOI: 10.5114/wo.2025.154077
Oktawia Sośnia, Elżbieta Iskierka-Jażdżewska, Anna Puła, Kamil Wiśniewski, Joanna Drozd-Sokołowska, Marta Morawska, Urszula Gosik, Dariusz Woszczyk, Agata Ogłoza, Kamil Wdowiak, Ewa Paszkiewicz-Kozik, Ewa Wąsik-Szczepanek, Mirosław Markiewicz, Magdalena Zawartko, Anna Kokoć, Anna Szumera-Ciećkiewicz, Monika Prochorec-Sobieszek, Dorota Jesionek-Kupnicka, Marcin Braun, Beata Gierej, Tadeusz Robak, Ewa Lech-Marańda, Bartosz Puła

[This corrects the article DOI: 10.5114/mp.2025.148753.].

[这更正了文章DOI: 10.5114/mp.2025.148753]。
{"title":"Correction for: Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study Group.","authors":"Oktawia Sośnia, Elżbieta Iskierka-Jażdżewska, Anna Puła, Kamil Wiśniewski, Joanna Drozd-Sokołowska, Marta Morawska, Urszula Gosik, Dariusz Woszczyk, Agata Ogłoza, Kamil Wdowiak, Ewa Paszkiewicz-Kozik, Ewa Wąsik-Szczepanek, Mirosław Markiewicz, Magdalena Zawartko, Anna Kokoć, Anna Szumera-Ciećkiewicz, Monika Prochorec-Sobieszek, Dorota Jesionek-Kupnicka, Marcin Braun, Beata Gierej, Tadeusz Robak, Ewa Lech-Marańda, Bartosz Puła","doi":"10.5114/wo.2025.154077","DOIUrl":"10.5114/wo.2025.154077","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.5114/mp.2025.148753.].</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 3","pages":"320-321"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12518206/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145304173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of radiofrequency ablation versus surgery for management of papillary thyroid microcarcinoma: a systematic review, meta-analysis, and meta-regression. 射频消融与手术治疗甲状腺乳头状微癌的疗效和安全性:系统回顾、荟萃分析和荟萃回归。
IF 1.3 Q2 ONCOLOGY Pub Date : 2025-01-01 Epub Date: 2025-09-09 DOI: 10.5114/wo.2025.153884
Hendra Zufry, Timotius Ivan Hariyanto

Introduction: The current evidence is ambiguous regarding the comparative efficacy and safety of radiofrequency ablation (RFA) versus surgery as thera-peutic options for papillary thyroid microcarcinoma (PTMC). The principal aim of this study was to clarify these uncertainties.

Material and methods: A thorough investigation was performed using the Cochrane Library, Europe PMC, Scopus, and Medline databases until January 20th, 2025, employing a combination of pertinent keywords. This review included studies that compared RFA and surgery for PTMC. We employed random-effects models to assess the mean difference (MD) and odds ratio (OR) for the reported outcomes.

Results: A total of 7 studies with 1,638 patients were included. Our meta- analysis indicated that RFA was associated with a shorter procedure time (MD -62.69 min; 95% CI: -78.33, -47.05, p < 0.00001), less blood loss (MD -24.13 ml; 95% CI: -30.02, -18.23, p < 0.00001), shorter hospitalization duration (MD -6.70 days; 95% CI: -8.85, -4.55, p < 0.00001), and lower total expenses (SMD -2.77; 95% CI: -4.27, -1.27, p = 0.0003) compared to surgery in PTMC patients. No significant difference in the tumor progression rate (p = 0.80), lymph node metastasis (p = 0.24), or recurrence rate (p = 0.38) was observed between RFA and surgery. In terms of safety, RFA exhibited fewer total complications (OR 0.33; 95% CI: 0.13-0.80, p = 0.01) than surgery.

Conclusions: RFA may serve as a feasible alternative for the treatment of PTMC in individuals who have opted against active surveillance or are ineligible for surgical intervention.

目前关于射频消融(RFA)与手术治疗甲状腺乳头状微癌(PTMC)的疗效和安全性的比较证据尚不明确。本研究的主要目的是澄清这些不确定性。材料和方法:使用Cochrane Library, Europe PMC, Scopus和Medline数据库进行了彻底的调查,直到2025年1月20日,使用相关关键词组合。本综述包括比较RFA和手术治疗PTMC的研究。我们采用随机效应模型来评估报告结果的平均差异(MD)和优势比(OR)。结果:共纳入7项研究,1638例患者。我们的荟萃分析表明,与PTMC患者的手术相比,RFA与更短的手术时间(MD -62.69分钟,95% CI: -78.33, -47.05, p < 0.00001)、更少的出血量(MD -24.13 ml, 95% CI: -30.02, -18.23, p < 0.00001)、更短的住院时间(MD -6.70天,95% CI: -8.85, -4.55, p < 0.00001)和更低的总费用(SMD -2.77, 95% CI: -4.27, -1.27, p = 0.0003)相关。RFA与手术在肿瘤进展率(p = 0.80)、淋巴结转移率(p = 0.24)、复发率(p = 0.38)方面无显著差异。安全性方面,RFA的总并发症比手术少(OR 0.33; 95% CI: 0.13-0.80, p = 0.01)。结论:RFA可作为治疗PTMC的可行替代方案,适用于那些选择不进行主动监测或不符合手术干预条件的个体。
{"title":"Efficacy and safety of radiofrequency ablation versus surgery for management of papillary thyroid microcarcinoma: a systematic review, meta-analysis, and meta-regression.","authors":"Hendra Zufry, Timotius Ivan Hariyanto","doi":"10.5114/wo.2025.153884","DOIUrl":"10.5114/wo.2025.153884","url":null,"abstract":"<p><strong>Introduction: </strong>The current evidence is ambiguous regarding the comparative efficacy and safety of radiofrequency ablation (RFA) versus surgery as thera-peutic options for papillary thyroid microcarcinoma (PTMC). The principal aim of this study was to clarify these uncertainties.</p><p><strong>Material and methods: </strong>A thorough investigation was performed using the Cochrane Library, Europe PMC, Scopus, and Medline databases until January 20<sup>th</sup>, 2025, employing a combination of pertinent keywords. This review included studies that compared RFA and surgery for PTMC. We employed random-effects models to assess the mean difference (MD) and odds ratio (OR) for the reported outcomes.</p><p><strong>Results: </strong>A total of 7 studies with 1,638 patients were included. Our meta- analysis indicated that RFA was associated with a shorter procedure time (MD -62.69 min; 95% CI: -78.33, -47.05, <i>p</i> < 0.00001), less blood loss (MD -24.13 ml; 95% CI: -30.02, -18.23, <i>p</i> < 0.00001), shorter hospitalization duration (MD -6.70 days; 95% CI: -8.85, -4.55, <i>p</i> < 0.00001), and lower total expenses (SMD -2.77; 95% CI: -4.27, -1.27, <i>p</i> = 0.0003) compared to surgery in PTMC patients. No significant difference in the tumor progression rate (<i>p</i> = 0.80), lymph node metastasis (<i>p</i> = 0.24), or recurrence rate (<i>p</i> = 0.38) was observed between RFA and surgery. In terms of safety, RFA exhibited fewer total complications (OR 0.33; 95% CI: 0.13-0.80, <i>p</i> = 0.01) than surgery.</p><p><strong>Conclusions: </strong>RFA may serve as a feasible alternative for the treatment of PTMC in individuals who have opted against active surveillance or are ineligible for surgical intervention.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 3","pages":"247-256"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12518203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145304196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LINE-1 retrotransposon activation drives age-associated inflammation via cytoplasmic cDNA-STING/type I interferon signalling: therapeutic potential of reverse transcriptase inhibition. LINE-1逆转录转座子激活通过细胞质cDNA-STING/ I型干扰素信号驱动年龄相关炎症:逆转录酶抑制的治疗潜力
IF 1.3 Q2 ONCOLOGY Pub Date : 2025-01-01 Epub Date: 2025-06-26 DOI: 10.5114/wo.2025.152369
Arshad Mehmood, Yue Zhu Xue, Habab Merghani Yassin, Mohammad Zubair, Syed Adnan Rahmat, Aftab Ahmad

Retrotransposable elements are harmful at several levels, and host surveillance systems fail to consider all these elements in severe effects. The key role of retrotransposon in aging and age-associated diseases remains unclear. We summarise whether LINE-1 retrotransposable elements transcriptio-nally derepress and activate type-I interferon response during cellular senescence. Type-I interferon response is the late senescence phenotype that maintains the senescence-associated secretory phenotype. Cytoplasmic LINE-1 cDNA activates type-I interferon response, while LINE-1 reverse transcriptase inhibitors suppress it. The nucleoside reverse transcriptase inhibitor lamivudine downregulates activation of type-I interferon and age- associated inflammation in tissues in the treatment of aging. Activation of retrotransposons is a key factor in sterile inflammation, which is a hallmark of aging, and LINE-1 reverse trans-criptase is an important target for the treatment of age-associated diseases. Nucleoside reverse transcriptase inhibitor lamivudine downregulates activation of type-I interferon and age-associated inflammation.

反转录转座因子在几个层面上都是有害的,宿主监测系统未能考虑到所有这些因子的严重影响。反转录转座子在衰老和年龄相关疾病中的关键作用尚不清楚。我们总结了LINE-1逆转录转座因子是否在细胞衰老过程中转录抑制和激活i型干扰素反应。i型干扰素反应是维持衰老相关分泌表型的晚期衰老表型。细胞质LINE-1 cDNA激活i型干扰素应答,而LINE-1逆转录酶抑制剂抑制它。核苷逆转录酶抑制剂拉米夫定在治疗衰老过程中下调i型干扰素的激活和与年龄相关的组织炎症。逆转录转座子的激活是无菌炎症的关键因素,而无菌炎症是衰老的标志,而LINE-1逆转录酶是治疗年龄相关疾病的重要靶点。核苷逆转录酶抑制剂拉米夫定下调i型干扰素和年龄相关炎症的激活。
{"title":"LINE-1 retrotransposon activation drives age-associated inflammation <i>via</i> cytoplasmic cDNA-STING/type I interferon signalling: therapeutic potential of reverse transcriptase inhibition.","authors":"Arshad Mehmood, Yue Zhu Xue, Habab Merghani Yassin, Mohammad Zubair, Syed Adnan Rahmat, Aftab Ahmad","doi":"10.5114/wo.2025.152369","DOIUrl":"10.5114/wo.2025.152369","url":null,"abstract":"<p><p>Retrotransposable elements are harmful at several levels, and host surveillance systems fail to consider all these elements in severe effects. The key role of retrotransposon in aging and age-associated diseases remains unclear. We summarise whether LINE-1 retrotransposable elements transcriptio-nally derepress and activate type-I interferon response during cellular senescence. Type-I interferon response is the late senescence phenotype that maintains the senescence-associated secretory phenotype. Cytoplasmic LINE-1 cDNA activates type-I interferon response, while LINE-1 reverse transcriptase inhibitors suppress it. The nucleoside reverse transcriptase inhibitor lamivudine downregulates activation of type-I interferon and age- associated inflammation in tissues in the treatment of aging. Activation of retrotransposons is a key factor in sterile inflammation, which is a hallmark of aging, and LINE-1 reverse trans-criptase is an important target for the treatment of age-associated diseases. Nucleoside reverse transcriptase inhibitor lamivudine downregulates activation of type-I interferon and age-associated inflammation.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 3","pages":"240-246"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12518201/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145304226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alpha-fetoprotein as a prognostic factor in alpha-fetoprotein-negative hepatocellular carcinoma - integration into post-resection prognostic nomograms. 甲胎蛋白作为甲胎蛋白阴性肝细胞癌的预后因素-纳入术后预后x线图。
IF 2.9 Q2 ONCOLOGY Pub Date : 2025-01-01 Epub Date: 2025-04-09 DOI: 10.5114/wo.2025.149087
Shinichi Ikuta, Tsukasa Aihara, Takayoshi Nakajima, Naoki Yamanaka

Introduction: This study aimed to validate the prognostic value of alpha- fetoprotein (AFP) in AFP-negative hepatocellular carcinoma (HCC) and develop an AFP-integrated nomogram for post-resection recurrence-free survival (RFS) and overall survival (OS).

Material and methods: This retrospective study analyzed 453 HCC patients with preoperative AFP ≤ 20 ng/ml who underwent curative resection, divided into training (n = 317) and validation (n = 136) cohorts. The optimal AFP cutoff was determined using maximized χ2 values. Nomograms were developed with repeated least absolute shrinkage and selection operator variable selection and stepwise Cox regression. Model performance was assessed using concordance (C-) indices, time-dependent area under the receiver operating characteristic curves (AUCs), calibration plots, and Kaplan-Meier (KM) curves.

Results: An alpha-fetoprotein cutoff of 7 ng/ml stratified patients for both RFS and OS (p < 0.001). The recurrence-free survival nomogram included AFP, age, sex, multiple tumors, and cirrhosis, while the OS nomogram incorporated AFP, albumin-bilirubin score, the up-to-7 criterion, des-γ-carboxy prothrombin, vascular invasion, and histological grade. In the training cohort, the nomograms demonstrated C-indices of 0.64 (95% CI: 0.60-0.68) for RFS and 0.72 (0.67-0.76) for OS. Validation cohort C-indices were 0.64 (0.62-0.65) for RFS and 0.67 (0.65-0.68) for OS. Time-dependent AUCs and calibration plots confirmed the predictive accuracy of the nomograms, and KM curves showed clear separation between high- and low-risk groups, further highlighting their clinical utility.

Conclusions: Alpha-fetoprotein retains prognostic value even within the clinically normal range for HCC. The AFP-integrated post-resection nomograms demonstrated acceptable predictive performance for AFP-negative patients, potentially enhancing personalized management strategies.

简介:本研究旨在验证甲胎蛋白(AFP)在AFP阴性肝细胞癌(HCC)中的预后价值,并开发一种用于术后无复发生存期(RFS)和总生存期(OS)的AFP综合nomogram。材料和方法:本回顾性研究分析了453例术前AFP≤20 ng/ml行根治性切除的HCC患者,分为训练组(n = 317)和验证组(n = 136)。采用最大χ2值确定AFP的最佳截止点。通过重复最小绝对收缩和选择算子变量选择和逐步Cox回归来开发nomogram。采用一致性(C-)指数、受试者工作特征曲线(auc)下的时变面积、校准图和Kaplan-Meier (KM)曲线来评估模型的性能。结果:RFS和OS分层患者的甲胎蛋白均为7 ng/ml (p < 0.001)。无复发生存图包括AFP、年龄、性别、多发肿瘤、肝硬化,OS包括AFP、白蛋白-胆红素评分、达-7标准、des-γ-羧基凝血酶原、血管侵犯、组织学分级。在训练队列中,模态图显示RFS的c指数为0.64 (95% CI: 0.60-0.68), OS的c指数为0.72(0.67-0.76)。验证队列c指数RFS为0.64 (0.62-0.65),OS为0.67(0.65-0.68)。随时间变化的auc和校准图证实了nomographic的预测准确性,KM曲线显示出高风险组和低风险组之间的明显分离,进一步突出了它们的临床实用性。结论:甲胎蛋白在HCC的临床正常范围内仍具有预后价值。对于afp阴性的患者,afp综合术后x线图显示出可接受的预测性能,潜在地增强了个性化的管理策略。
{"title":"Alpha-fetoprotein as a prognostic factor in alpha-fetoprotein-negative hepatocellular carcinoma - integration into post-resection prognostic nomograms.","authors":"Shinichi Ikuta, Tsukasa Aihara, Takayoshi Nakajima, Naoki Yamanaka","doi":"10.5114/wo.2025.149087","DOIUrl":"https://doi.org/10.5114/wo.2025.149087","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to validate the prognostic value of alpha- fetoprotein (AFP) in AFP-negative hepatocellular carcinoma (HCC) and develop an AFP-integrated nomogram for post-resection recurrence-free survival (RFS) and overall survival (OS).</p><p><strong>Material and methods: </strong>This retrospective study analyzed 453 HCC patients with preoperative AFP ≤ 20 ng/ml who underwent curative resection, divided into training (<i>n</i> = 317) and validation (<i>n</i> = 136) cohorts. The optimal AFP cutoff was determined using maximized χ<sup>2</sup> values. Nomograms were developed with repeated least absolute shrinkage and selection operator variable selection and stepwise Cox regression. Model performance was assessed using concordance (C-) indices, time-dependent area under the receiver operating characteristic curves (AUCs), calibration plots, and Kaplan-Meier (KM) curves.</p><p><strong>Results: </strong>An alpha-fetoprotein cutoff of 7 ng/ml stratified patients for both RFS and OS (<i>p</i> < 0.001). The recurrence-free survival nomogram included AFP, age, sex, multiple tumors, and cirrhosis, while the OS nomogram incorporated AFP, albumin-bilirubin score, the up-to-7 criterion, des-γ-carboxy prothrombin, vascular invasion, and histological grade. In the training cohort, the nomograms demonstrated C-indices of 0.64 (95% CI: 0.60-0.68) for RFS and 0.72 (0.67-0.76) for OS. Validation cohort C-indices were 0.64 (0.62-0.65) for RFS and 0.67 (0.65-0.68) for OS. Time-dependent AUCs and calibration plots confirmed the predictive accuracy of the nomograms, and KM curves showed clear separation between high- and low-risk groups, further highlighting their clinical utility.</p><p><strong>Conclusions: </strong>Alpha-fetoprotein retains prognostic value even within the clinically normal range for HCC. The AFP-integrated post-resection nomograms demonstrated acceptable predictive performance for AFP-negative patients, potentially enhancing personalized management strategies.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 1","pages":"69-76"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lactobacillus brevis YNH inhibits proliferation of HeLa cells and promotes their apoptosis by modulating the PI3K/AKT pathway. 短乳杆菌YNH通过调节PI3K/AKT通路抑制HeLa细胞增殖,促进HeLa细胞凋亡。
IF 2.9 Q2 ONCOLOGY Pub Date : 2025-01-01 Epub Date: 2025-03-18 DOI: 10.5114/wo.2025.148642
Liang He, Dingji Tan, Rui Zhu, Jinglin Zhao, Hongli Yin, Ming Duan, Xin Li, Wen Fan, Zhiqin Yang, Xin Wang, Hongying Yang

Introduction: Existing treatments for cervical cancer have side effects on the human body. Some lactobacilli inhibit tumour progression in a strain-specific manner without toxic side effects.

Material and methods: We explored whether Lactobacillus brevis YNH isolated from the vagina has anti-cervical cancer effects by performing Cell Counting Kit-8 assays, flow cytometry, JC-1 staining, and western blotting. Transcriptome sequencing was performed to determine the possible mechanism. Xenograft tumour model mice that were orally administered Lactobacillus brevis YNH were used to validate the anticancer effects in vivo.

Results: Our study revealed that Lactobacillus brevis YNH downregulated the expression of cyclin E1 and CDK2, resulting in cell cycle arrest at S phase and inhibition of HeLa cell proliferation. In addition, HeLa cells treated with Lactobacillus brevis YNH significantly promoted the cleavage of caspase-3 and caspase-8, and increased the expression of Bax. Also, the mitochondrial membrane potential decreased, which induced apoptosis of HeLa cells. Most of the differentially expressed genes were enriched in the PI3K/AKT pathway, indicating that Lactobacillus brevis YNH might exert its anticancer effects through the PI3K/AKT pathway. Most importantly, we found that the tumour volume of mice was significantly smaller than control group after orally administered Lactobacillus brevis YNH, and biochemical results showed that Lactobacillus brevis YNH had no toxic side effects on the liver or kidney, suggesting that Lactobacillus brevis YNH has anti-cervical cancer effects in vivo.

Conclusions: This study revealed the anti-cervical cancer effects of Lactobacillus brevis YNH, providing a new candidate bioactive substance for the treatment of cervical cancer.

导读:现有的宫颈癌治疗方法对人体有副作用。一些乳酸菌以一种菌株特异性的方式抑制肿瘤的进展,而没有毒副作用。材料和方法:我们通过细胞计数试剂盒-8、流式细胞术、JC-1染色和western blotting检测从阴道分离的短乳杆菌YNH是否具有抗宫颈癌作用。进行转录组测序以确定可能的机制。用口服短乳杆菌YNH的异种移植物肿瘤模型小鼠验证其体内抗癌作用。结果:我们的研究发现,短乳杆菌YNH下调cyclin E1和CDK2的表达,导致细胞周期阻滞在S期,抑制HeLa细胞的增殖。此外,短乳杆菌YNH处理的HeLa细胞显著促进了caspase-3和caspase-8的裂解,增加了Bax的表达。线粒体膜电位降低,诱导HeLa细胞凋亡。大多数差异表达基因富集于PI3K/AKT通路,提示短乳杆菌YNH可能通过PI3K/AKT通路发挥其抗癌作用。最重要的是,我们发现口服短乳杆菌YNH后小鼠的肿瘤体积明显小于对照组,生化结果显示短乳杆菌YNH对肝脏和肾脏均无毒副作用,提示短乳杆菌YNH在体内具有抗宫颈癌作用。结论:本研究揭示了短乳杆菌YNH的抗宫颈癌作用,为宫颈癌治疗提供了新的候选生物活性物质。
{"title":"<i>Lactobacillus brevis</i> YNH inhibits proliferation of HeLa cells and promotes their apoptosis by modulating the PI3K/AKT pathway.","authors":"Liang He, Dingji Tan, Rui Zhu, Jinglin Zhao, Hongli Yin, Ming Duan, Xin Li, Wen Fan, Zhiqin Yang, Xin Wang, Hongying Yang","doi":"10.5114/wo.2025.148642","DOIUrl":"https://doi.org/10.5114/wo.2025.148642","url":null,"abstract":"<p><strong>Introduction: </strong>Existing treatments for cervical cancer have side effects on the human body. Some lactobacilli inhibit tumour progression in a strain-specific manner without toxic side effects.</p><p><strong>Material and methods: </strong>We explored whether <i>Lactobacillus brevis</i> YNH isolated from the vagina has anti-cervical cancer effects by performing Cell Counting Kit-8 assays, flow cytometry, JC-1 staining, and western blotting. Transcriptome sequencing was performed to determine the possible mechanism. Xenograft tumour model mice that were orally administered <i>Lactobacillus brevis</i> YNH were used to validate the anticancer effects <i>in vivo</i>.</p><p><strong>Results: </strong>Our study revealed that <i>Lactobacillus brevis</i> YNH downregulated the expression of cyclin E1 and CDK2, resulting in cell cycle arrest at S phase and inhibition of HeLa cell proliferation. In addition, HeLa cells treated with <i>Lactobacillus brevis</i> YNH significantly promoted the cleavage of caspase-3 and caspase-8, and increased the expression of Bax. Also, the mitochondrial membrane potential decreased, which induced apoptosis of HeLa cells. Most of the differentially expressed genes were enriched in the PI3K/AKT pathway, indicating that <i>Lactobacillus brevis</i> YNH might exert its anticancer effects through the PI3K/AKT pathway. Most importantly, we found that the tumour volume of mice was significantly smaller than control group after orally administered <i>Lactobacillus brevis</i> YNH, and biochemical results showed that <i>Lactobacillus brevis</i> YNH had no toxic side effects on the liver or kidney, suggesting that <i>Lactobacillus brevis</i> YNH has anti-cervical cancer effects <i>in vivo</i>.</p><p><strong>Conclusions: </strong>This study revealed the anti-cervical cancer effects of <i>Lactobacillus brevis</i> YNH, providing a new candidate bioactive substance for the treatment of cervical cancer.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 1","pages":"55-68"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144023250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A case series of immune checkpoint inhibitor-induced gastritis. 免疫检查点抑制剂诱发胃炎1例。
IF 1.3 Q2 ONCOLOGY Pub Date : 2025-01-01 Epub Date: 2025-09-16 DOI: 10.5114/wo.2025.153801
Athanasia Karavasili, Melina Yerolatsite, George Zarkavelis, Vaia Karafousia, Nanteznta Torounidou, Anna-Lea Amylidi, Eleftherios Kampletsas

Immune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of various solid tumors due to their proven efficacy. However, their use is associated with immune-related adverse events (irAEs), which arise from the immune response activated by ICIs. Gastrointestinal irAEs are among the most common and often present as diarrhea or colitis, conditions that can sometimes require discontinuation of ICI therapy. Although irAE gastritis is less frequently reported, it can lead to severe complications, such as gastrorrhagia. Diagnosing immune-related gastritis early can be challenging due to its diverse clinical presentations. While glucocorticoids and other immunosuppressive therapies are standard treatments for irAEs, the optimal management strategy and dosing for immune-related gastritis remain unclear. This case series on ga-stritis caused by ICI therapy aims to provide clinicians with valuable insights into this complex condition and its management.

免疫检查点抑制剂(ICIs)已成为治疗各种实体肿瘤的基石,由于其证实的有效性。然而,它们的使用与免疫相关不良事件(irAEs)有关,这是由ICIs激活的免疫反应引起的。胃肠性肠内感染是最常见的,通常表现为腹泻或结肠炎,有时需要停止肠内感染治疗。虽然irAE胃炎较少报道,但它可导致严重的并发症,如胃出血。由于其临床表现多样,早期诊断免疫相关性胃炎可能具有挑战性。虽然糖皮质激素和其他免疫抑制疗法是raes的标准治疗方法,但免疫相关性胃炎的最佳治疗策略和剂量仍不清楚。本病例系列的目的是为临床医生提供有价值的见解,以了解这种复杂的情况及其管理。
{"title":"A case series of immune checkpoint inhibitor-induced gastritis.","authors":"Athanasia Karavasili, Melina Yerolatsite, George Zarkavelis, Vaia Karafousia, Nanteznta Torounidou, Anna-Lea Amylidi, Eleftherios Kampletsas","doi":"10.5114/wo.2025.153801","DOIUrl":"10.5114/wo.2025.153801","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of various solid tumors due to their proven efficacy. However, their use is associated with immune-related adverse events (irAEs), which arise from the immune response activated by ICIs. Gastrointestinal irAEs are among the most common and often present as diarrhea or colitis, conditions that can sometimes require discontinuation of ICI therapy. Although irAE gastritis is less frequently reported, it can lead to severe complications, such as gastrorrhagia. Diagnosing immune-related gastritis early can be challenging due to its diverse clinical presentations. While glucocorticoids and other immunosuppressive therapies are standard treatments for irAEs, the optimal management strategy and dosing for immune-related gastritis remain unclear. This case series on ga-stritis caused by ICI therapy aims to provide clinicians with valuable insights into this complex condition and its management.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 3","pages":"316-319"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12518205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145304167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical outcomes of fractionated stereotactic radiotherapy for uveal melanoma - a Polish single-centre experience. 分级立体定向放疗治疗葡萄膜黑色素瘤的临床结果-波兰单中心经验。
IF 1.3 Q2 ONCOLOGY Pub Date : 2025-01-01 Epub Date: 2025-11-03 DOI: 10.5114/wo.2025.155789
Adam Deja, Paulina Baluch, Marta Wróblewska-Zierhoffer, Emilia Zwolińska, Maria Radomiak, Piotr Milecki, Iwona Rospond-Kubiak

Introduction: The aim of the study is to present the results of the first Polish cohort of patients treated with fractionated stereotactic radiotherapy (fSRT) for large and/or juxtapapillary uveal melanoma (UM).

Material and methods: The medical records of the patients who underwent the fSRT for UM in Poznań (cooperation between the Department of Ophthalmology, Poznań University of Medical Sciences and Greater Poland Cancer Centre) in 2014-2020 were retrospectively reviewed. The diagnosis was made in each case after detailed clinical examination, ultrasound and/or choroidal biopsy in selected patients. The irradiation protocol was to deliver 50 Gy in 5 fractions.

Results: We identified 27 patients, 12 men, 15 women, with a median age of 61.5 years. The median longitudinal basal diameter of treated tumours was 11.7 mm (range 5.2-17.8 mm), median thickness - 7.5 mm (range 1.7-9.7 mm). The median follow-up was 38 months (range 5-101 months). We observed neovascular glaucoma in 9 (34%) patients, which was the reason for globe removal in 3 (11%) of them. There was one local tumour recurrence (3.8%) with extraorbital extension 6 years post-treatment. Local tumour control in our cohort was 96.2%. By the study end, 5 (18.5%) patients died, including 3 (11%) of metastatic disease. The final visual acuity was logMAR 0.3 or better for 3 patients (11%).

Conclusions: As reported also by other authors, fSRT could be a useful treatment modality for selected large and/or juxtapapillary melanomas.

简介:该研究的目的是介绍波兰第一个队列患者接受分割立体定向放疗(fSRT)治疗大的和/或乳头旁葡萄膜黑色素瘤(UM)的结果。材料和方法:回顾性分析2014-2020年在波兹纳瓦(波兹纳瓦医科大学眼科与大波兰癌症中心合作)接受UM的fSRT患者的医疗记录。每个病例的诊断是经过详细的临床检查,超声和/或脉络膜活检选定的患者。辐照方案是将50戈瑞的辐射分成5份。结果:我们确定了27例患者,男性12例,女性15例,中位年龄61.5岁。治疗肿瘤的中位纵向基底直径为11.7 mm(范围5.2-17.8 mm),中位厚度为- 7.5 mm(范围1.7-9.7 mm)。中位随访为38个月(范围5-101个月)。我们在9例(34%)患者中观察到新生血管性青光眼,这是其中3例(11%)患者摘除眼球的原因。治疗6年后有1例局部肿瘤复发(3.8%)伴眶外扩张。本队列局部肿瘤控制率为96.2%。研究结束时,5例(18.5%)患者死亡,其中3例(11%)死于转移性疾病。3例(11%)患者的最终视力达到logmar0.3或更好。结论:正如其他作者所报道的那样,fSRT可能是一种有效的治疗方式,用于选择大的和/或乳头旁黑色素瘤。
{"title":"Clinical outcomes of fractionated stereotactic radiotherapy for uveal melanoma - a Polish single-centre experience.","authors":"Adam Deja, Paulina Baluch, Marta Wróblewska-Zierhoffer, Emilia Zwolińska, Maria Radomiak, Piotr Milecki, Iwona Rospond-Kubiak","doi":"10.5114/wo.2025.155789","DOIUrl":"10.5114/wo.2025.155789","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of the study is to present the results of the first Polish cohort of patients treated with fractionated stereotactic radiotherapy (fSRT) for large and/or juxtapapillary uveal melanoma (UM).</p><p><strong>Material and methods: </strong>The medical records of the patients who underwent the fSRT for UM in Poznań (cooperation between the Department of Ophthalmology, Poznań University of Medical Sciences and Greater Poland Cancer Centre) in 2014-2020 were retrospectively reviewed. The diagnosis was made in each case after detailed clinical examination, ultrasound and/or choroidal biopsy in selected patients. The irradiation protocol was to deliver 50 Gy in 5 fractions.</p><p><strong>Results: </strong>We identified 27 patients, 12 men, 15 women, with a median age of 61.5 years. The median longitudinal basal diameter of treated tumours was 11.7 mm (range 5.2-17.8 mm), median thickness - 7.5 mm (range 1.7-9.7 mm). The median follow-up was 38 months (range 5-101 months). We observed neovascular glaucoma in 9 (34%) patients, which was the reason for globe removal in 3 (11%) of them. There was one local tumour recurrence (3.8%) with extraorbital extension 6 years post-treatment. Local tumour control in our cohort was 96.2%. By the study end, 5 (18.5%) patients died, including 3 (11%) of metastatic disease. The final visual acuity was logMAR 0.3 or better for 3 patients (11%).</p><p><strong>Conclusions: </strong>As reported also by other authors, fSRT could be a useful treatment modality for selected large and/or juxtapapillary melanomas.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 4","pages":"367-369"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12721234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145821748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgical learning curve and flap survival in head and neck microvascular reconstruction using arterial and venous couplers. 应用动脉和静脉耦合器重建头颈部微血管的手术学习曲线和皮瓣存活率。
IF 1.3 Q2 ONCOLOGY Pub Date : 2025-01-01 Epub Date: 2025-10-30 DOI: 10.5114/wo.2025.155692
Adam Gałązka, Karolina Bieńkowska-Pluta, Monika Paszkowska, Magdalena Misiak-Gałązka, Katarzyna Stawarz

Introduction: This study evaluated the surgical learning curve associated with the simultaneous use of arterial and venous couplers, alongside flap survival outcomes, in head and neck cancer reconstruction.

Material and methods: A total of 127 pa-- tients (51 women, 76 men; aged 30-84 years) underwent microvascular free tissue transfer using the Synovis coupler device. Three flap types were used: radial forearm free flap, anterolateral thigh flap, and free fibula flap. Flap viability was assessed clinically during the first 7 postoperative days and at monthly follow-ups for up to one year. Operative time was recorded to monitor procedural efficiency.

Results: Four flap failures were observed. The cumulative sum analysis of surgical time revealed three distinct learning phases: Initial Learning (cases 1-30), Performance Improvement (31-58), and Plateau (59 onward). Piecewise linear regression confirmed minimal trend predictability in the first two phases (R2 = 0.08), while Phase 3 demonstrated a strong linear decline in operative time (R2 = 0.82), indicating attainment of surgical proficiency.

Conclusions: While hand-sewn anastomosis remains the standard in microsurgical reconstruction, this study supports arterial couplers as a safe, efficient alternative with a manageable learning curve -encouraging broader adoption in clinical practice.

本研究评估了在头颈癌重建中同时使用动脉和静脉耦合器的手术学习曲线,以及皮瓣的存活结果。材料和方法:共有127例患者(女性51例,男性76例,年龄30-84岁)采用Synovis耦合器进行微血管游离组织移植。采用前臂桡侧游离皮瓣、大腿前外侧游离皮瓣和腓骨游离皮瓣三种皮瓣类型。术后前7天及每月随访1年,对皮瓣活力进行临床评估。记录手术时间,监测手术效率。结果:皮瓣失败4例。手术时间的累积和分析显示了三个不同的学习阶段:初始学习(病例1-30),表现改善(病例31-58)和平稳期(病例59)。分段线性回归证实了前两个阶段的趋势可预测性最小(R2 = 0.08),而第三阶段显示了手术时间的强烈线性下降(R2 = 0.82),表明达到了手术熟练程度。结论:虽然手工缝合吻合仍然是显微外科重建的标准,但本研究支持动脉耦合器作为一种安全、有效的替代方法,具有可管理的学习曲线,鼓励在临床实践中广泛采用。
{"title":"Surgical learning curve and flap survival in head and neck microvascular reconstruction using arterial and venous couplers.","authors":"Adam Gałązka, Karolina Bieńkowska-Pluta, Monika Paszkowska, Magdalena Misiak-Gałązka, Katarzyna Stawarz","doi":"10.5114/wo.2025.155692","DOIUrl":"10.5114/wo.2025.155692","url":null,"abstract":"<p><strong>Introduction: </strong>This study evaluated the surgical learning curve associated with the simultaneous use of arterial and venous couplers, alongside flap survival outcomes, in head and neck cancer reconstruction.</p><p><strong>Material and methods: </strong>A total of 127 pa-- tients (51 women, 76 men; aged 30-84 years) underwent microvascular free tissue transfer using the Synovis coupler device. Three flap types were used: radial forearm free flap, anterolateral thigh flap, and free fibula flap. Flap viability was assessed clinically during the first 7 postoperative days and at monthly follow-ups for up to one year. Operative time was recorded to monitor procedural efficiency.</p><p><strong>Results: </strong>Four flap failures were observed. The cumulative sum analysis of surgical time revealed three distinct learning phases: Initial Learning (cases 1-30), Performance Improvement (31-58), and Plateau (59 onward). Piecewise linear regression confirmed minimal trend predictability in the first two phases (R<sup>2</sup> = 0.08), while Phase 3 demonstrated a strong linear decline in operative time (R<sup>2</sup> = 0.82), indicating attainment of surgical proficiency.</p><p><strong>Conclusions: </strong>While hand-sewn anastomosis remains the standard in microsurgical reconstruction, this study supports arterial couplers as a safe, efficient alternative with a manageable learning curve -encouraging broader adoption in clinical practice.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 4","pages":"333-340"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12721231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145821812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Wspolczesna Onkologia-Contemporary Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1